ArticleLancet regional health. Americas2022
Prevalence of glucose 6-phosphate dehydrogenase deficiency in highly malaria-endemic municipalities in the Brazilian Amazon: A region-wide screening study.
Article in Lancet regional health. Americas, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase-Deficient Patients in the Brazilian Amazon (ALTPRIM).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Health-care provider compliance with a revisedLancet regional health. Americas · 2026Article
- Evaluation of the Diagnostic Accuracy of the Quantitative Point-of-Care SD Biosensor Standard G6PD Test for Assessment of G6PD Deficiency in Infectious Diseases.International journal of laboratory hematology · 2026Article
- Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.Blood global hematology · 2026Article
- Strengthening the health systems at national level for malaria elimination in the Greater Mekong Subregion countries: a qualitative study.Infectious diseases of poverty · 2026Article
- The Landscape of Malaria in a Five-Decade Institution in the State of Amazonas: Historical Trends, Scientific Contributions, and Research Priorities.Revista da Sociedade Brasileira de Medicina Tropical · 2026Review
- The cost-effectiveness of tafenoquine following screening with STANDARD™ G6PD screening for the treatment of vivax malaria in the Brazilian Public Health System.Lancet regional health. Americas · 2025Article
- Article
- Assessing tafenoquine implementation in Brazil: a qualitative evaluation of perceptions of healthcare providers and Plasmodium vivax patients (QualiTRuST Study).Malaria journal · 2024Observational
- Functional analysis of G6PD variants associated with low G6PD activity in the All of Us Research Program.Genetics · 2024Article
- Perspectives of healthcare professionals on training for quantitative G6PD testing during implementation of tafenoquine in Brazil (QualiTRuST Study).PLoS neglected tropical diseases · 2024Article
- Functional Analysis of G6PD Variants Associated With Low G6PD Activity in the All of Us Research Program.medRxiv : the preprint server for health sciences · 2024Article
- Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.The Lancet. Global health · 2024Observational
- Prevalence and correlates of childhood anemia in the MINA-Brazil birth cohort study.Revista de saude publica · 2024Article
- Association ofPathogens (Basel, Switzerland) · 2023Article
- Individual variation in Plasmodium vivax malaria risk: Are repeatedly infected people just unlucky?PLoS neglected tropical diseases · 2023Review
- Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication.Tropical diseases, travel medicine and vaccines · 2022Review
- Quantitative G6PD Deficiency Screening in Routine Malaria Diagnostic Units in the Brazilian Amazon (SAFEPRIM): An Operational Mixed-Methods Study.Pathogens (Basel, Switzerland) · 2022Article
- Prevalence of G6PD candidate variants in malaria-endemic populations of northern Brazil.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
- High prevalence of G6PD mutations in blood donors from the Brazilian Amazon region.Blood transfusion = Trasfusione del sangueArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Difficulties associated with the assessment of glucose-6-phosphate dehydrogenase deficiency (G6PDd), particularly in remote areas, hinders the safe use of 8-aminoquinolines such as primaquine (PQ) and tafenoquine against Methods: This cross-sectional study was conducted in 41 malaria-endemic municipalities of six states in the Brazilian Amazon, between 2014 and 2018. Male individuals were screened for G6PDd using the qualitative Fluorescent Spot Test using fingerpick-collected whole blood samples. Point and interval estimates of the G6PDd prevalence were calculated for each state. Deficient samples were genotyped for the most prevalent variants in the Amazon. Frequencies of Interpretation: This is one of the largest surveys ever conducted in Latin America, covering the entire malaria endemic area in the Brazilian Amazon. These results indicate that an important proportion of the population is at risk of hemolysis if exposed to PQ and its congener drug tafenoquine. The adoption of G6PDd screening protocols is essential to ensure the safety of individuals treated with those drugs and should also be considered when implementing malaria elimination strategies. Findings: A total of 14,847 individuals were included, of which 5.6% presented G6PDd. The state of Acre had the highest G6PDd prevalence (8.3%), followed by Amapá (5.8%), Pará (5.7%), Rondônia (5.4%), Roraima (4.2%) and Amazonas (4.0%). From 828 genotyped samples, African A Funding: Brazilian Ministry of Health; Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.